← All trials
NCT01144195
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2009
- Primary completion
- Dec 1, 2011
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 80
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socialsLead sponsor
- Hospital Universitari Son DuretaOverall official - principal investigator
- Hospital de GranollersOverall official - principal investigator
- Consorci Sanitari de TerrassaOverall official - principal investigator
- Hospital de DeniaOverall official - principal investigator
- Hospital General de ManresaOverall official - principal investigator
- Universitat de VicOverall official - principal investigator
- Rovira i Virgili UniversityOverall official - principal investigator
- Hospital Universitario Arnau de Vilanova de LleidaOverall official - principal investigator
- AmgenCollaborator
- University of BarcelonaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.